Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1935530 | 0.94 | ADRB2 (0.45) | ADRB2ADRB1ADRB3ATMTSHR | |
| SCHEMBL27689281 | 0.89 | THRB (0.42) | TSHRCA1CA2THRB | |
| SCHEMBL1937796 | 0.87 | — | — | |
| SCHEMBL618225 | 0.86 | — | — | |
| SCHEMBL6178131 | 0.85 | THRB (0.41) | TSHRCA1CA2THRB | |
| SCHEMBL6178964 | 0.82 | THRB (0.47) | TSHRCA1CA2THRB | |
| SCHEMBL8536239 | 0.81 | ALDH1A1 (0.41) | TSHRALDH1A1LMNATHRBSMN1; SMN2 | |
| SCHEMBL6132441 | 0.80 | — | — | |
| SCHEMBL5342 | 0.79 | — | — | |
| Butyl Formate SCHEMBL17559280 | 0.78 | ATM (0.39) | ADRB2ADRB1ADRB3ATMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466688-A | Oxazole derivatives and their use in the treatment of diabetes and obesity | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | disclosed |
| CN-101460469-A | Compound (I) | ASTRAZENECA AB (SE) | 2009-06-17 | — | — | CN | disclosed |
| CN-101115731-A | Oxadiazole derivatives as DGAT inhibitors | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | CN | disclosed |
| EP-0945445-B9 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
| CN-1130351-C | 1,5-benzodiazepine derivatives | ZERIA PHARM CO LTD (JP) | 2003-12-10 | — | — | CN | disclosed |
| EP-0945445-B1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| CN-1246850-A | 1,5-benzodiazepine derivatives | ZERIA PHARM CO LTD (JP) | 2000-03-08 | — | — | CN | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |